AccoladeACCD
ACCD
About: Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.
Employees: 2,400
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
6% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 31
5% more capital invested
Capital invested by funds: $247M [Q2] → $259M (+$11.2M) [Q3]
1% more funds holding
Funds holding: 149 [Q2] → 150 (+1) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 49
2.4% less ownership
Funds ownership: 86.34% [Q2] → 83.93% (-2.4%) [Q3]
85% less call options, than puts
Call options by funds: $1.01M | Put options by funds: $6.57M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
27%
downside
Avg. target
$6.02
13%
downside
High target
$7.03
2%
upside
2 analyst ratings
0 positive
0%
2 neutral
100%
0 negative
0%
Stifel David Grossman 48% 1-year accuracy 12 / 25 met price target | 2%upside $7.03 | Hold Downgraded | 9 Jan 2025 |
Morgan Stanley Ricky Goldwasser 50% 1-year accuracy 8 / 16 met price target | 27%downside $5 | Equal-Weight Maintained | 17 Dec 2024 |
Financial journalist opinion
Based on 9 articles about ACCD published over the past 30 days
Neutral
PRNewsWire
1 week ago
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Accolade
NEW YORK , Jan. 10, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Accolade (NASDAQ: ACCD) and its board of directors concerning the proposed acquisition of the company by Transcarent. Stockholders will receive $7.03 for each share of Accolade stock that they hold.
Negative
Zacks Investment Research
1 week ago
Accolade (ACCD) Reports Q3 Loss, Lags Revenue Estimates
Accolade (ACCD) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.28 per share a year ago.
Neutral
Business Wire
1 week ago
ACCOLADE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Accolade, Inc. - ACCD
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Accolade, Inc. (NasdaqGS: ACCD) to Transcarent. Under the terms of the proposed transaction, shareholders of Accolade will receive $7.03 in cash for each share of Accolade that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the considera.
Positive
Benzinga
1 week ago
Why Is Accolade Stock Trading Over 100% On Tuesday?
Transcarent agreed to buy Accolade Inc ACCD Wednesday for $621 million.
Neutral
Business Wire
1 week ago
Shareholder Alert: Ademi LLP Investigates Whether Accolade, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Accolade (NASDAQ: ACCD) for possible breaches of fiduciary duty and other violations of law in its transaction with the Transcarent. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Accolade stockholders will receive $7.03 per share in cash, which represents a total equity value of ap.
Positive
GeekWire
1 week ago
Healthcare M&A: Transcarent paying $621M to acquire Seattle-based health benefits firm Accolade
Seattle-based Accolade is set to go private again in a deal to be acquired by Transcarent that brings together two health benefits companies.
Neutral
Business Wire
1 week ago
ACCD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Accolade, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Accolade, Inc. (NASDAQ: ACCD) to Transcarent for $7.03 per share in cash is fair to Accolade shareholders. Halper Sadeh encourages Accolade shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Accolade and its board.
Neutral
Business Wire
1 week ago
Transcarent To Acquire Accolade
SAN FRANCISCO & SEATTLE--(BUSINESS WIRE)-- #HealthWayFinding--Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, announced that they have entered into a definitive agreement under which Transcarent will acquire Accolade for $7.03 per share in cash, which represents a total equity value of approximately $621M. This strategic combination, which has been unanimously approved by the Boards of Directors of both companies, w.
Neutral
GlobeNewsWire
1 week ago
Transcarent To Acquire Accolade
Combined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment
Neutral
GlobeNewsWire
1 month ago
Accolade to Announce Fiscal Third Quarter 2025 Financial Results
SEATTLE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal third quarter 2025 financial results on Thursday, January 9, 2024 after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.
Charts implemented using Lightweight Charts™